Abstract

N’Chiepo Kouadio Davy*, Seka Evrad Narcisse, Agbanglanon Douhoue Patricia, Tbouda Mohammed, Siham Jaba, Elkacemi Hanane, Kebdani Tayeb and Elmajjaoui Saana and Benjaafar Noureddine

ABSTRACT

verrucous carcinoma (VC) of the Vulva is extremely rare, accounting for less than 1% of vulvar cancer. Effectively, it is characterization by a slow growing, no metastasis or lymph node involvement. The aim of this study was to report our experience with this disease. Three patients with VC who were treated at National Institute of Oncology between 2013 and 2018. Clinicopathological characteristics, treatment and follow-up were extracted from the medical records. The average age at diagnosis was 66 years. The average time from the onset of symptoms to diagnosis was 21 months. All patients complained of a vulvar mass or nodule, accompanied by vulvar pruritus and/or pain, which was main reasons for consultation. A preliminary pathological diagnosis of squamous cell carcinoma was made in two cases. Surgical treatment included partial vulvectomy or radical vulvectomy with uni- or bilateral lymph node dissection in the groin. Tumor size ranged from 50 to 105 mm. In the final histology, we concluded VC of the vulva staged IB (2 cases) and staged III (1 case) with marginal limits in two cases. Concurrent radiochemotherapy was performed in one case, exclusive radiotherapy in one case and only surgery in one case. Radiotherapy approaches toxicity observed were grade 2 proctitis and radiodermatitis in all cases with renal toxicity in concurrent radiochemotherapy. The mean follow-up was 43 months with no recurrence. Only one patient observed after 1-year follow-up, lichen which was resected with wide local excision. Conclusion: Vulvar VC is a distinct type of slow-growing, tumor with unclear etiology. Surgery is the most effective treatment. Radiotherapy approaches are considered depending on disease stage and risk factors.